吸烟史对软组织肉瘤患者无肺转移生存期的影响
Impact of Smoking History on Pulmonary Metastasis-free Survival in Patients With Soft-tissue Sarcoma.
作者信息
Matsuoka Masatake, Okamoto Masanori, Soma Tamotsu, Yokota Isao, Arai Ryuta, Onodera Tomohiro, Kondo Eiji, Iwasaki Norimasa, Hiraga Hiroaki
机构信息
Department of Musculoskeletal Oncology, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Department of Orthopaedic Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
出版信息
Cancer Diagn Progn. 2021 May 3;1(2):89-94. doi: 10.21873/cdp.10013. eCollection 2021 May-Jun.
BACKGROUND/AIM: Although smoking history is predictive of poor pulmonary metastasis-free survival (PMFS) in patients with epithelial tumors, the impact of smoking history on PMFS in those with soft-tissue sarcoma (STS) is not known.
PATIENTS AND METHODS
Patients undergoing treatment for STS at our institutes between 2008 and 2017 were enrolled. Patients were excluded if they had metastatic lesion, or had a histopathological classification demonstrating small round-cell sarcoma. The impact of smoking history on PMFS and overall survival was examined with multivariate analysis using a Cox proportional hazards model.
RESULTS
A total of 250 patients were retrospectively reviewed. Patients with smoking history had worse PMFS on multivariate analysis (hazard ratio=2.00, 95% confidence interval=1.12-3.60). On the other hand, smoking history did not significantly affect overall survival (hazard ratio=1.26, 95% confidence interval=0.61-2.58).
CONCLUSION
Patients with STS need to be followed-up by frequent clinical assessments if they have a smoking history.
背景/目的：尽管吸烟史可预测上皮性肿瘤患者无肺转移生存期（PMFS）较差，但吸烟史对软组织肉瘤（STS）患者PMFS的影响尚不清楚。
患者与方法
纳入2008年至2017年间在我们机构接受STS治疗的患者。如果患者有转移病灶或组织病理学分类显示为小圆细胞肉瘤，则将其排除。使用Cox比例风险模型通过多变量分析检查吸烟史对PMFS和总生存期的影响。
结果
共回顾性分析了250例患者。多变量分析显示，有吸烟史的患者PMFS较差（风险比=2.00，95%置信区间=1.12-3.60）。另一方面，吸烟史对总生存期无显著影响（风险比=1.26，95%置信区间=0.61-2.58）。
结论
有吸烟史的STS患者需要通过频繁的临床评估进行随访。
Zotero 插件